Testing effectiveness (Phase 2)Study completedNCT02162446What this trial is testing68Ga-OPS202 Study for Diagnostic Imaging of GEP NETWho this might be right forGastroenteropancreatic Neuroendocrine Tumors Ipsen 12
Testing effectiveness (Phase 2)Study completedNCT02955069What this trial is testingStudy of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)Who this might be right forWell-differentiated Non-functional NET of Thoracic OriginWell-differentiated Non-functional NET of Gastrointestinal OriginWell-differentiated Non-functional NET of Pancreatic Origin+1 more Novartis Pharmaceuticals
Not applicableStudy completedNCT03791346What this trial is testingPancreatectomy for NET: External Evaluation of WHO 2017 Grading SystemWho this might be right forPancreatic Surgery University Hospital, Montpellier 138
Not applicableLooking for participantsNCT07554560What this trial is testingNutrition Intervention for Pancreatic CancerWho this might be right forPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Neuroendocrine Tumor (NET) Children's Hospital of Philadelphia 18
Not applicableNo Longer AvailableNCT01980732What this trial is testing68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive TumorsWho this might be right forCarcinoid TumorsIslet Cell (Pancreatic NET)Other Neuroendocrine Tumors Andrei Iagaru
Testing effectiveness (Phase 2)Looking for participantsNCT04924075What this trial is testingBelzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)Who this might be right forPheochromocytoma/ParagangliomaPancreatic Neuroendocrine TumorVon Hippel-Lindau Disease+2 more Merck Sharp & Dohme LLC
Not applicableAvailableNCT07262970What this trial is testingIntermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a TumorWho this might be right forTumor-associated Hyperinsulinism (Tumor HI) Rezolute
Not applicableLooking for participantsNCT07463872What this trial is testingManagement of Pancreatic Cystic Lesions Using Artificial Intelligence Based on EUS and Multimodal DataWho this might be right forPancreatic Cystic LesionMucinous Cystadenoma of PancreasIntraductal Papillary Mucinous Neoplasm of Pancreas+3 more Huazhong University of Science and Technology 500
Not applicableLooking for participantsNCT06246630What this trial is testingIn Vitro Organoid Drug Sensitivity-Guided Treatment for Advanced Pancreatic Neuroendocrine TumorWho this might be right forAdvanced Pancreatic Neuroendocrine Tumor Ruijin Hospital 20
Testing effectiveness (Phase 2)Study completedNCT02936323What this trial is testingPEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung CancersWho this might be right forNeuroendocrine TumorsCarcinoma, Small Cell LungNeuroendocrine Carcinoma Tarveda Therapeutics 89
Large-scale testing (Phase 3)Active Not RecruitingNCT04919226What this trial is testingLutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSEWho this might be right forNeuroendocrine Tumors ITM Solucin GmbH 259
Not applicableNot Yet RecruitingNCT07014254What this trial is testingTherapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive MalignanciesWho this might be right forPancreatic Ductal Adenocarcinoma (PDAC)Adenocarcinoma of the StomachColorectal Cancer Metastatic+1 more Xijing Hospital 20
Testing effectiveness (Phase 2)Study completedNCT02132468What this trial is testingA Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated BiomarkersWho this might be right forNeuroendocrine Tumors Mateon Therapeutics 18
Testing effectiveness (Phase 2)UnknownNCT04029428What this trial is testingPeptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR OverexpressionWho this might be right forNeuroendocrine Tumors University of Warmia and Mazury 150
Not applicableUnknownNCT05448157What this trial is testing68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NETWho this might be right forNeuroendocrine Tumor CarcinoidNeuroendocrine Tumor of PancreasGep Net European Institute of Oncology 20
Testing effectiveness (Phase 2)Ended earlyNCT02736448What this trial is testing177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine TumorsWho this might be right forGastro-entero-pancreatic Neuroendocrine Tumors Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 35
Testing effectiveness (Phase 2)Looking for participantsNCT06505395What this trial is testingA Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)Who this might be right forGastrointestinal Neuroendocrine Pancreatic Tumor CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 90
Testing effectiveness (Phase 2)UnknownNCT04194125What this trial is testingPersonalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine CancerWho this might be right forNeuroendocrine Tumors University of Warmia and Mazury 25
Large-scale testing (Phase 3)Active Not RecruitingNCT03049189What this trial is testingEfficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET PatientsWho this might be right forNeuroendocrine Tumors ITM Solucin GmbH 324
Large-scale testing (Phase 3)Study completedNCT00510068What this trial is testingEfficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine TumorsWho this might be right forAdvanced Neuroendocrine Tumors of Pancreatic Origin Novartis Pharmaceuticals 410